Romiplostim: new drug. Thrombocytopenic purpura: for selected patients, with close monitoring.
D004311:Double-Blind Method; D017277:Drug Approval; D005060:Europe; D006470:Hemorrhage / Q000188:drug therapy; D006801:Humans; D009965:Orphan Drug Production; D010976:Platelet Count; D011696:Purpura, Thrombocytopenic / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D011961:Receptors, Fc / Q000008:administration & dosage / Q000627:therapeutic use*; D053628:Receptors, Thrombopoietin / Q000819:agonists*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013926:Thrombopoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D011961:Receptors, Fc; D053628:Receptors, Thrombopoietin; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin; C488777:romiplostim